
Redefining the Standard of Care in Quantifying Chronic Liver Disease



Introducing Velacur™

The first handheld 3D liver tissue assessment tool with diagnostic accuracy comparable to MRI elastography.

Velacur[™] is a breakthrough, point-of-care solution for assessing and managing chronic liver disease.

- III A portable, handheld solution using technology similar to MRI elastography, Velacur[™] quantifies liver disease using 3D tissue sampling with steady state waves
- In Machine learning ensures parenchyma tissue is located, resulting in a confident assessment of liver health in all body types
- Immediate and reliable steatosis and fibrosis measurements are generated at point of care with diagnostic accuracy comparable to MRI

Activation

An activation pad is placed under the patient's back to create steady state waves similar to MRI elastography

Ultrasound Scan

Machine learning ensures optimal probe position followed by guided 3D sweep with a handheld ultrasound

Readout


Accurate and reliable steatosis and fibrosis measurements are generated for immediate clinical assessment






The procedure is a quick, comfortable and non-invasive 3-step process. It can be performed by a clinician in as little as five minutes enabling increased practice productivity and patient throughput. State-of-the-art technology results in a more accurate and reliable clinical assessment of chronic liver disease, making Velacur™ the preferred first-line non-invasive liver assessment tool.

	Velacur™	FibroScan®
Depth of Liver Tissue Samples	15 cm	3.5-7.0 cm
Volume of Liver Sampled	100.0 cm ³	3.14 cm ³
3D Data Acquisition	Yes	Not available
Single Probe for All Body Types	Yes	No
Machine-Learning Guidance	Yes	No
Accuracy Similar to MRI	Yes	No




30x larger tissue sampling contributes to higher accuracy and reliability.





Attenuation to PDFF Comparison



Results show Velacur[™] strongly agrees with MRI in terms of fat (attenuation) and fibrosis (elasticity) measurements.

VS MRI & Biopsy

Velacur[™] offers added benefits over MRI & biopsy with respect to quantification of steatosis and staging of fibrosis, practice management and patient acceptance.

- Increases practice management efficiency
- Portable for use in any location
- Performed in 5 minutes by a non-specialist
- Immediate readout and interpretation of results
- Cost-effective solution
- Minimal upfront investment with potential new revenue stream to provider
- Available reimbursement without pre-authorization
- I Convenient, comfortable and safe for the patient



Designed for today's practice



Convenient

Accessible

· l Cost-effective

66

Velacur[™] is a very timely and needed solution for improved management of patients with documented or suspected liver disease. The ability for accurate and rapid point of care screening of patients, allows physicians to address the urgent NAFLD health crisis in a primary care setting, with cost-effective referral for specialist evaluation.

 Dr. Nezam Afdhal MD, DSc Chief of Gastroenterology, Hepatology and Nutrition, Beth Israel Deaconess Medical Center Professor of Medicine, Harvard Medical School



Health Insights You Can Count On

560-828 West 10th Ave Vancouver, BC V5Z 1M9 sonicincytes.com

1-800-881-0096

VelacurTM Fast. Accurate. Intelligent.

© COPYRIGHT 2020 SONIC INCYTES MEDICAL CORP. SINA-1005, Rev A, 08/20

Cover image provided by BioDigital